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1236Objective: Preformed anti-human leukocyte antigen antibodies have been associated with prolonged wait times
and increased mortality in orthotopic heart transplantation. We used United Network for Organ Sharing data to
examine panel reactive antibody titers in patients bridged to transplant with left ventricular assist devices.
Methods: This was a retrospective review of the United Network for Organ Sharing dataset for all patients
bridged to orthotopic heart transplantation with a HeartMate II or HeartMate XVE (Thoratec Corp, Pleasanton,
Calif) from January 2004 to December 2009. Patients were primarily stratified by device type and secondarily
grouped for comparisons by high (>25%) versus low (0%) panel reactive antibody activity (class I and II). Out-
comes included survival (30-day and 1-year), treated rejection in the year after orthotopic heart transplantation,
and primary graft dysfunction. Cox proportional hazards regression examined 30-day and 1-year survival.
Results: A total of 871 patients (56.1%) received the HeartMate II device, and 673 patients (43.9%) received the
HeartMate XVE device. Patients with high panel reactive antibody had longer duration on the wait list (205 days
[interquartile range, 81–344] vs 124 days [interquartile range, 51–270],P¼ .01).High panel reactive antibody class
II was more common in patients with the HeartMate XVE device (51/547 [9.3%] vs 42/777 [5.4%], P<.001).
When the entire cohort was examined together, there was no 30-day or 1-year survival difference based on panel
reactive antibody activity. Device type did not affect post-orthotopic heart transplantation survival, and panel reac-
tive antibody activity was not associated with worse mortality in Cox regression. Although panel reactive antibody
activity did not affect rejection in the year after orthotopic heart transplantation for either device type, high panel
reactive antibody class II was associated with higher rates of primary graft dysfunction for both devices (P<.05).
Conclusions: This is the largest modern study to examine the impact of detailed panel reactive antibody infor-
mation in patients bridged to transplant. High panel reactive antibody levels do not affect drug-treated rejection
episodes in the first year post-orthotopic heart transplantation; however, there is an associated higher rate of pri-
mary graft dysfunction, regardless of device type. Highly sensitized patients bridged to transplant experience ex-
cellent survival outcomes after orthotopic heart transplantation. (J Thorac Cardiovasc Surg 2011;142:1236-45)Supplemental material is available online.e Divisions of Cardiac Surgerya and Cardiology,b and The Bloomberg School
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The Journal of Thoracic and Cardiovascular SurPast studies have considered left ventricular assist device
(LVAD) implantation to be a sensitizing event, resulting
in elevations of anti-human leukocyte antibody (HLA)
levels.1-4 Panel reactive antibody (PRA) levels are
frequently used to quantify this sensitization. The Food
and Drug Administration approval of LVAD therapy as
a bridge to heart transplantation has led to increasing
numbers of patients awaiting orthotopic heart
transplantation (OHT) with LVADs in place.5 Although
some studies have cited increased mortality in highly sensi-
tized patients bridged to transplant who undergo transplan-
tation, particularly with older-generation pulsatile flow
devices,6-8 there are other studies that document
equivalent post-OHT survival in sensitized and nonsensi-
tized patients.9 Also, patients with high PRA levels under-
going conventional OHT are known to experience longer
wait-list time and worse 1-year survival.10 However,
many of these studies are limited by small sample size
and continually evolving laboratory techniques. It is unclear
whether the observed outcome differences persist on a na-
tional scale among all US patients bridged to transplant ingery c November 2011
Abbreviations and Acronyms
HLA ¼ human leukocyte antibody
HMII ¼ HeartMate II
LVAD ¼ left ventricular assist device
OHT ¼ orthotopic heart transplantation
PGD ¼ primary graft dysfunction
PRA ¼ panel reactive antibody
UNOS ¼ United Network for Organ Sharing
XVE ¼ HeartMate XVE
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Xthe modern era of immunomodulatory therapy. Therefore,
we used United Network for Organ Sharing (UNOS) data
to examine outcomes among highly sensitized patients
bridged to OHT.
MATERIALS AND METHODS
Data Source
The UNOS Standard Transplant Analysis and Research database repre-
sents an open cohort of prospectively collected donor specific and follow-
up data from October 1987 to December 2009. The dataset used comprises
all US patients undergoing thoracic organ transplantation, with follow-up
to June 2010. No patient or center identifiers were included, and the study
was granted institutional review board exemption.
Study Design
This study was a retrospective cohort design, including adult (>17
years) patients undergoing primary OHT as a bridge to transplant with
the HeartMate II (HMII) or HeartMate XVE (XVE) device (Thoratec
Corp, Pleasanton, Calif) from January 2004 to December 2009. PRAmajor
histocompatibility class is not distinguished before 2004 in the UNOS da-
tabase, and thus the study began in 2004. Exclusion criteria included in-
complete ventricular assist device data, heart-lung transplantation, prior
OHT, and missing PRA information. The cohort was stratified according
to device type (HMII vs XVE).
Panel Reactive Antibody
PRA levels closest to the time of transplant were used in all patients. In-
terventions to desensitize patients and timing of ventricular assist device
implant are not available in the UNOS database. Thus, PRA levels at listing
and peak PRA levels were not evaluated. Highly sensitized patients were
defined as having a PRA greater than 25%, and nonsensitized patients
were defined as having a PRA of 0%. Strata of PRA activity were defined
according to the following groups: 0%, greater than 0% to 10%, greater
than 10% to 25%, and greater than 25%. Class I and II PRA levels
were first examined separately. Because sensitization has been reported
in the pediatric OHT literature as an elevated PRA level regardless of class,
we also defined a composite PRA score as the highest PRA level in either
class.11 Comparisons between high (>25%) and low (0%) PRA activity
were performed for both device types. Additional PRA information not
contained within the Standard Transplant Analysis and Research file was
provided by UNOS. Specifically, 4 categories of PRA assay methods
were identified: (1) cytotoxicity assays, (2) enzyme-linked immunosorbent
assays, (3) flow cytometry assays, and (4) other.
Variables Examined and Outcome Measures
The dataset contains more than 400 preoperative, intraoperative, and
postoperative variables. Variables examined included primary diagnosis;The Journal of Thoracic and Cardemographics (age, sex, race, education, and insurance); pre-OHT me-
chanical ventilation or intensive care unit admission; comorbidities (diabe-
tes mellitus, percent ideal body weight, serum creatinine levels, and
hypertension); and transplant variables (ischemic time, HLA mismatch,
transplant year, and wait-list time). In addition, hemodynamic measure-
ments (mean pulmonary artery pressure, pulmonary vascular resistance,
and cardiac index) were examined. Donor variables examined were age,
race, sex, cytomegalovirus status, diabetes, and cigarette use.
The primary end point was 1-year mortality. Secondary outcomes exam-
ined were short term mortality (30-day), rejection requiring treatment
within the first year after OHT, primary graft dysfunction (PGD), and
drug-treated infection. In the UNOS database, PGD is self-reported and de-
fined by each individual center.
Statistical Analysis
We compared baseline characteristics between the high versus low PRA
groups (class I and II separately) by the Student t test (continuous variables)
and chi-square test (categoric variables). Survivals of 30 days, 90 days, and
1 year were estimated using the Kaplan–Meier method, because these time
intervals have adequate follow-up in this dataset. TheMantel–Cox log-rank
test was used to compare survival estimates according to PRA activity. The
entire cohort was analyzed according to the Kaplan–Meier method. Sepa-
rate Kaplan–Meier analysis was performed for XVE and HMII to assess the
impact of device type.
A multivariable Cox proportional hazards regression model estimated
risk of death with censoring for death, loss to follow-up, and administrative
reasons (end of study period). To construct the multivariable model, inde-
pendent covariates with potential for confounding were first tested in a uni-
variate fashion. In addition to variables associated with mortality on
exploratory analysis (P<.2), those with biological plausibility and previ-
ously recognized risk factors were incorporated in a forward and backward
stepwise fashion into the multivariable model. The likelihood ratio test and
Akaike’s information criterion in a nested model approach were used to
identify which covariates increased the explanatory power of the model.
This method favors more parsimonious models. Because the multivariable
model was developed with case-wise deletion, all covariates with greater
than 15%missing data were not included. The final model for 1-year mor-
tality incorporated the following covariates: recipient age, heart failure
cause, race, recipient serum creatinine, recipient serum bilirubin, pre-
OHT infection requiring intravenous antibiotics, preoperative mechanical
ventilation, allograft ischemic time, center volume, device type (XVE vs
HMII), and PRA activity. Although the model was explored with PRA ac-
tivity as a categoric variable or incorporating strata of PRA activity, the
Akaike’s information criterion favored PRA as a categoric variable
(>25%). Visual inspection of complementary log-log plots and testing of
Schoenfeld residuals for each variable confirmed that the assumption of
proportional hazards had not been violated.
Means are presented with standard deviations, and medians are pre-
sented with their interquartile range. Hazard ratios are displayed with
95% confidence intervals. Statistical testing was performed using STATA
software (version 11; StataCorp LP, College Station, Tex).
RESULTS
Cohort Statistics
From 2004 to 2009, 1672 patients underwent OHT as
a bridge to transplant with an XVE or HMII device in the
UNOS database. In regard to device type, 938 patients
(56.1%) received an HMII and 734 patients (43.9%) re-
ceived an XVE. PRA information was missing in 128 pa-
tients (7%); thus, the final cohort consisted of 1544
patients (n ¼ 673, XVE; n ¼ 871, HMII). The mean age
of the cohort was 52  12 years, and 84.8% were malediovascular Surgery c Volume 142, Number 5 1237
TABLE 1. Distribution of panel reactive antibody levels by class
Class
% PRA activity
0% 1%–10% 11%–25% >25%
I (N ¼ 1544) 1038 (67.2%) 194 (12.6%) 94 (6.1%) 218 (14.1%)
II (N ¼ 1324) 1078 (81.5%) 105 (7.9%) 48 (3.6%) 93 (7.0%)
Composite PRA 976 (63.3%) 212 (13.8%) 114 (7.4%) 240 (15.6%)
XVE (N ¼ 673)
I 437 (64.9%) 91 (13.5%) 46 (6.8%) 99 (14.7%)
II 424 (77.5%) 47 (8.6%) 25 (4.6%) 51 (9.3%)*
Composite
PRA
410 (60.9%) 93 (13.8%) 57 (8.5%) 113 (16.8%)
HMII (N ¼ 871)
I 601 (69.0%) 103 (11.8%) 48 (5.5%) 119 (13.7%)
II 654 (84.2%) 58 (7.5%) 23 (3.0%) 42 (5.4%)*
Composite
PRA
566 (65.1%) 119 (13.7%) 57 (6.6%) 127 (14.6%)
*By chi-square analysis, more patients with the XVE device were highly sensitized to
PRA class II.
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X(n ¼ 1309). Recipient race distribution was white, 70.4%
(n¼ 1087); African-American, 21.3% (n¼ 329); Hispanic,
6.0% (n ¼ 92); and other, 2.3% (n ¼ 36). Donor race dis-
tribution was white, 70.3% (n¼ 1086); African-American,
14.8% (n ¼ 228); Hispanic, 12.7% (n ¼ 196); and other,
2.2% (n ¼ 34). During the study period, 234 patients
(15.2%) died and 178 patients (11.5%) did not survive 1
year. One-year incidence of death was 14.7 deaths/100
person-years. The median follow-up was 12 months (inter-
quartile range, 5–36). Throughout the study period, the
number of adult OHT recipients with a bridge to transplant
increased, with 139 (7.0% of all OHT) in 2004 and 453
(20.4% of all OHT) in 2009.
Class I PRA information was available for 1544 patients
and class II for 1324 patients. The breakdown of PRA strata
is depicted in Table 1. The majority of patients had a PRA
level of 0% for class I (67.2%) and class II (81.4%). A mi-
nority of patients were highly sensitized (PRA>25%) for
class I (14.1%) and class II (7.0%). When considering the
composite PRA (highest PRAvalue in either class), 240 pa-
tients (15.6%) were highly sensitized (PRA>25%). There
were 163 patients (10.5%) who were highly sensitized in
one class but not the other. The median PRA for highly sen-
sitized patients (>25% PRA) who underwent OHT was
58% and 51% for class I and class II, respectively. There
were patients with a PRA as high as 100% in each class
who underwent OHT. No differences were detected in
PRA class I levels by device type; however, more patients
with an XVE device were highly sensitized by PRA class
II levels (P<.01). In regard to the type of PRA class I assays
performed, cytotoxicity was used in 393 patients (25.5%),
enzyme-linked immunosorbent assays were used in 125 pa-
tients (8.1%), flow cytometry was used in 740 patients
(47.9%), and other methods were used in 286 patients
(18.5%).1238 The Journal of Thoracic and Cardiovascular SurBaseline Characteristics
There were few baseline characteristics that differed
between the XVE and HMII groups. Patients in the
XVE group tended to be male and to have a history of hy-
pertension. They were also more likely to be hospitalized
before OHT and more frequently required preoperative
dialysis and intensive care unit care. There were subtle
differences in insurance status between the XVE and
HMII groups, but these differences were small. The
HMII group experienced more time on the wait list.
Race, heart failure cause, and the remaining variables
were evenly distributed between the 2 device types and
are shown in Table 2.
Differences in patients with PRA 0% versus highly sen-
sitized patients (PRA>25%) are shown in Table 3, for both
class I and II. Many clinical characteristics were similar;
however, highly sensitized patients tended to be younger
and female. African-American OHT recipients were also
more likely to be sensitized. Patients with high class I activ-
ity spent a longer time on thewait list, but this difference did
not reach significance for class II (Table E1). Baseline char-
acteristics of patients in the composite class exhibited sim-
ilar patterns (data not shown).
Survival
When the entire cohort was analyzed together, overall
survival at 1 year was 86.7%. When comparing survival
by device type, 1-year survival estimates were similar
between the XVE and HMII groups (XVE, 87.2% vs
HMII, 85.1%; P ¼ .5). No differences were detected
when examining survival based on PRA activity. Patients
with high class I PRA activity (>25%) had equivalent
30-day and 1-year survival as patients with PRA activity
of 0% (30-day, 95.6% vs 93.8%; P ¼ .3; 1-year, 86.7%
vs 84.5%; P ¼ .5). Likewise, no differences were found
when examining class II PRA activity (30-day, 94.7% vs
93.7%; P ¼ .5; 1-year, 90.7% vs 85.4%; P ¼ .3). Ka-
plan–Meier 1-year survival estimates are depicted in
Figure 1. A comparison was also made in patients with ex-
tremely high PRA class I levels (>90%, n ¼ 43) versus
PRA of 0%, and no differences were observed for 1-year
survival (87.4% vs 84.3%, P ¼ .9). Subgroup analysis
was performed in patients with idiopathic cardiomyopathy,
and no significant differences in survival were detected for
30-day or 1-year mortality, regardless of PRA activity
stratification.
By considering each PRA assay independently, we com-
pared 1-year Kaplan–Meier survival estimates in patients
with PRA greater than 25% versus patients with PRA
0%. We repeated this analysis comparing patients with
PRA greater than 90% versus 0%. Regardless of PRA as-
say type, there were no significant differences in 1-year sur-
vival between sensitized and nonsensitized patients by
either stratification (>25% vs 0%, or>90% vs 0%).gery c November 2011
TABLE 2. Baseline characteristics stratified by device type
Variable
XVE
(N ¼ 673)
HMII
(N ¼ 871)
P
value*
Demographics and
comorbidities
Age, y 51.9  10.6 51.7  12.3 .8
Male gender 599 (89%) 710 (82%) <.001
Hypertension 213/426 (50.0%) 86/217 (39.6%) .01
Diabetes 223/661 (33.7%) 265/868 (30.5%) .2
Creatinine, mg/mL 1.3  0.6 1.3  0.8 .8
Preoperative dialysis 38/658 (5.8%) 26/852 (3.0%) <.001
Total bilirubin,
mg/dL
1.1  1.8 1.2  2.2 .4
Body mass index 28.6  5.2 27.7  12.8 .07
Idiopathic
cardiomyopathy
241/582 (41.4%) 351/723 (48.5%)
Ischemic
cardiomyopathy
326/582 (56.0%) 355/723 (49.1%)
Race
White 475 (70.6%) 612 (70.3%) .6
Black 146 (21.7%) 183 (21.0%)
Hispanic 40 (6.0%) 52 (6.0%)
Insurance and
education
Private insurance 386/673 (57%) 466/870 (53.5%) .05
Medicare 174/673 (25.8%) 267/870 (30.7%)
Medicaid 82/673 (12.2%) 113/870 (13.0%)
Other pay 31/673 (4.6%) 24/870 (2.8%)
College education 245/513 (47.7%) 343/680 (50.4%) .4
Acuity and pulmonary
function
Cardiac index,
L/min/BSA
2.3  0.7 2.4  0.7 .2
Mean PA pressure,
mm Hg
28.7  10.7 28.1  10.7 .3
PCWP, mm Hg 19.1  10.0 18.4  9.8 .2
Hospitalized 299/673 (44.4%) 238/870 (27.3%) <.001
ICU pre-OHT 147/673 (21.8%) 111/870 (12.8%) <.001
Preoperative
ventilator support
12/673 (1.8%) 10/871 (1.1%) .3
Donor and transplant
variables
Age, y 31.2  11.8 31.4  11.4 .7
Male gender 547/673 (81.3%) 675/871 (77.5%) .07
Cigarette use 144/668 (21.6%) 162/860 (18.8%) .2
Diabetes 20/670 (3.0%) 23/868 (2.7%) .7
Hypertension 147/673 (21.8%) 217/867 (25.0%) .1
Creatinine, mg/dL 1.3  1.0 1.3  1.0 .7
Inotropic support 378/672 (56.2%) 452/865 (52.2%) .1
CMV mismatch 172/673 (25.6%) 227/871 (26.0%) .8
HLA mismatch 348/572 (60.8%) 450/785 (57.3%) .2
Time on wait-list, d 118 [43–292] 155 [68–287] <.001
Ischemic time, h 3.4 1.1 3.3  1.1 .3
BSA, Body surface area; PA, pulmonary artery; PCWP, pulmonary capillary wedge
pressure; ICU, intensive care unit;CMV, cytomegalovirus;HLA, human leukocyte an-
tigen. *P value from Student t test, chi-square test, or Wilcoxon rank-sum test. Con-
tinuous variables with standard deviations (interquartile range for time on wait-list).
Categoric variables with whole numbers and percentages.
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After risk adjustment with Cox multivariable analysis,
high sensitization by class I or class II PRA activity was
not associated with an increased hazard of 30-day (Table
E2) or 1-year mortality (Table 4). For 30-day mortality,
African-American race, higher recipient serum creatinine,
congenital heart failure cause, preoperative recipient me-
chanical ventilation, and prolonged allograft ischemic time
were all associated with an increased hazard of death. On
1-year mortality analysis, recipient age, African-American
race, higher recipient serum creatinine, preoperative infec-
tion requiring intravenous antibiotics, and prolonged allo-
graft ischemic time all increased the risk of mortality.
Device type, center volume, and PRA activity did not affect
the hazard of death for 30-day or 1-year mortality.Rejection and Complications
The incidence of drug-treated rejection within the first
year after OHT was similar in patients with high class I
PRA activity compared with patients with 0% activity.
There were also no differences for patients with high class
II PRA activity (Table E1). More than 10% of the patients
in this cohort had missing information in the UNOS data-
base for this outcome; however, there was a trend for high
class II activity (84/329, 25.5% vs 13/37, 35.4%,
P ¼ .2). The occurrence of PGD as coded in the UNOS da-
tabase was higher in patients with high PRA class I (110/
1035, 10.6% vs 36/218, 16.5%; P ¼ .01) and patients
with high PRA class II activity (99/1075, 9.2% vs 22/93,
23.7%; P<.01). Rates of drug-treated infection were unaf-
fected by PRA activity (Table E1).T
XDISCUSSION
In this national registry study using UNOS data, highly
sensitized patients bridged to OHT with an LVAD have
equivalent survival as patients bridged to transplant with
low PRA activity. On univariate Kaplan–Meier analysis
and in a risk-adjusted multivariable Cox analysis, high
PRA activity was not associated with increased 30-day or
1-year survival in patients bridged to transplant. However,
highly sensitized patients continue to experience longer
wait-list times and have higher rates of PGD, although
this definition is poorly characterized in the UNOS data-
base. Given the small absolute differences observed for
1-year mortality, a study would require an estimated 900 pa-
tients in both PRA activity groups to be adequately powered
to conclusively determine no effect on mortality. However,
achieving greater statistical power than our study would be
technically difficult, because this study used the largest na-
tional registry available to examine a cohort of patients
bridged to transplant.
PRA evaluation in OHT candidates has been used to de-
tect circulating antibodies to a random and broad array ofdiovascular Surgery c Volume 142, Number 5 1239
TABLE 3. Baseline characteristics stratified by panel reactive antibody class I and class II
Variable
Class I Class II
PRA 0%
(N ¼ 1038)
PRA>25%
(N ¼ 218) P value*
PRA 0%
(N ¼ 1078)
PRA>25%
(N ¼ 93) P value*
Demographics and comorbidities
Age, y 52.2  11.5 50.2  12.0 .03 52.0  11.6 49.2  12.2 .02
Female gender 118/1038 (11.4%) 75/218 (34.4%) <.001 139/1078 (12.9%) 39/93 (41.9%) <.001
Hypertension 201/434 (46.3%) 43/88 (48.9%) .6 181/404 (44.8%) 21/43 (48.8%) .6
Diabetes 325/1032 (31.5%) 63/215 (29.3%) .5 329/1071 (30.7%) 29/91 (31.9%) .8
Creatinine, mg/mL 1.3  0.7 1.2  0.9 .4 1.3  0.6 1.1  0.5 .01
Preoperative dialysis 39/1012 (3.8%) 11/215 (5.1%) .4 43/1053 (4.1%) 4/90 (4.4%) .9
Total bilirubin, mg/dL 1.2  2.3 1.0 1.5 .4 1.2  2.1 0.9  0.7 .2
Body mass index 27.9  5.1 27.8  5.9 .6 28.3  11.8 27.5  5.3 .5
Idiopathic cardiomyopathy 403/1038 (38.8%) 79/218 (36.2%) .5 536/1078 (49.7%) 48/93 (51.6%) .9
Ischemic cardiomyopathy 476/1038 (45.9%) 85/218 (39.0%) .06 459/1078 (42.6%) 37/93 (39.8%)
Race
White 768/1038 (74.0%) 129/218 (59.2%) <.001 760 (70.5%) 52 (55.9%) .04
Black 185/1038 (17.8%) 74/218 (33.9%) 229 (21.2%) 32 (34.4%)
Hispanic 61/1038 (5.9%) 10/218 (4.6%) 63 (5.8%) 5 (5.4%)
Insurance and education
Private insurance 580/1037 (55.9%) 114/218 (52.3%) .1 603/1077 (56.0%) 51/93 (54.8%) <.001
Medicare 294/1037 (28.3%) 63/218 (28.9%) 322/1077 (29.9%) 19/93 (20.4%)
Medicaid 131/1037 (12.6%) 27/218 (12.4%) 131/1077 (12.2%) 16/93 (17.2%)
Other pay 32/1037 (3.1%) 14/218 (6.4%) 21/1077 (1.9%) 7/93 (7.5%)
College education 402/808 (49.8%) 73/164 (44.5%) .2 421/821 (51.3%) 34/74 (46.0%) .4
Acuity and pulmonary function
Cardiac index, L/min/BSA 2.4  0.7 2.4  0.7 .8 2.3  0.7 2.4  0.9 .4
Mean PA pressure, mm Hg 28.4  10.9 28.4  10.8 .9 28.5  11.0 28.6  11.3 .9
PCWP, mm Hg 18.8  10.0 18.1  9.8 .4 18.8  10.0 18.4  9.9 .7
Hospitalized 355/1037 (34.2%) 81/218 (37.2%) .4 383/1077 (35.6%) 36/93 (38.7%) .5
ICU pre-OHT 176/1037 (17.0%) 39/218 (17.9%) .7 194/1077 (18.0%) 19/93 (20.4%) .5
Preoperative ventilator support 15/1038 (1.5%) 4/218 (1.8%) .7 20/1078 (1.9%) 0/93 (0%) .2
Donor and transplant variables
Age, y 31.0  11.3 32.6  12.3 .06 31.6  11.5 30.5  12.2 .4
Male gender 920/1038 (88.6%) 143/218 (65.6%) <.001 849/1078 (78.7%) 70/93 (75.3%) .4
Cigarette use 211/1026 (20.6%) 39/216 (18.1%) .4 216/1070 (20.2%) 16/92 (17.4%) .5
Diabetes 25/1033 (2.4%) 9/218 (4.1%) .2 34/1075 (3.2%) 5/93 (5.4%) .3
Hypertension 255/1035 (24.6%) 37/218 (17.0%) .01 251/1075 (23.3%) 23/93 (23.5%) .8
Creatinine, mg/dL 1.3  1.0 1.3  1.0 .8 1.3  0.9 1.2  0.8 .3
Inotropic support 561/1032 (54.3%) 117/217 (54.0%) .9 574/1073 (53.5%) 51/93 (54.8%) .8
CMV mismatch 629/1033 (60.9%) 115/218 (52.8%) .03 290/1078 (26.9%) 15/93 (16.1%) .02
HLA mismatch 546/909 (60.1%) 97/193 (50.3%) .01 572/957 (59.7%) 44/83 (53.0%) .2
Time on wait-list, d 124 [51–270] 205 [81–344] <.001 137 [56–280] 150 [66–279] .4
Ischemic time, h 3.3  1.1 3.4  1.1 .3 3.4  1.1 3.3  1.1 .2
BSA, Body surface area; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; ICU, intensive care unit; CMV, cytomegalovirus; HLA, human leukocyte antigen.
*P value from Student t test, chi-square test, or Wilcoxon rank-sum test. Continuous variables with standard deviations (interquartile range for time on wait-list). Categoric vari-
ables with whole numbers and percentages.
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Xdonor lymphocytes. Given the constraints on ischemic time
in cardiac transplantation, most patients do not routinely
undergo prospective crossmatching. However, some centers
use the PRA activity levels to guide which patients should
undergo a prospective crossmatch, and positive T-cell cross-
match has been associated with worse 1-year mortality.12
Because of past observations that patients with high PRA
have worse outcomes after OHT, these patients are com-
monly only offered local allografts so that prospective1240 The Journal of Thoracic and Cardiovascular Surcrossmatching can be performed. As such, their donor
pool is contracted and they experience longer wait-list
times.
This study was confined to the years 2004 to 2009, which
may explain different findings from studies conducted in the
1990s.3,4,12-14 The differences in wait-list time suggest that
sensitized patients are treated differently by transplant
centers. It may be that available treatments or improve-
ments in immunomodulatory therapy are responsible forgery c November 2011
FIGURE 1. Kaplan–Meier estimates of 1-year survival of patients with
high versus low PRA class I activity (A) and patients with high versus
low PRA class II activity (B). PRA, Panel reactive antibody.
Arnaoutakis et al Cardiothoracic Transplantationthe equivalent outcomes as nonsensitized patients. In the
past, sensitization may have been associated with worse
outcomes because available therapies were less effective.
Moving forward it will be important to understand if theTABLE 4. Cox multivariable hazards regression for 1-year mortality
Variable
Class
HR 95% C
PRA>25% 1.02 0.65–1.
Recipient age, y 1.02 1.00–1.
Idiopathic cardiomyopathy — Referen
Ischemic cardiomyopathy 1.24 0.83–1.
Congenital 1.14 0.53–2.
White — Referen
African-American 2.06 1.35–3.
Hispanic 1.18 0.54–2.
Recipient serum creatinine, mg/mL 1.32 1.16–1.
Recipient serum bilirubin, mg/mL 1.00 0.95–1.
Preoperative infection requiring IV antibiotics 1.51 1.02–2.
Preoperative mechanical ventilation 2.21 0.82–5.
Allograft ischemic time, h 1.17 1.02–1.
High annual center volume (>12) 0.95 0.63–1.
HMII device 1.14 0.80–1.
HR,Hazard ratio; CI, confidence interval; IV, intravenous. *Cox multivariable analysis perf
II model examining class II PRA activity.
The Journal of Thoracic and Caroutcomes observed in this study are because PRA levels
are less relevant in the current era of immunogenetics test-
ing, immunomodulatory therapy, and perioperative care. If
so, this would argue in favor of performing transplants in
these patients more aggressively, resulting in shorter wait
times. Alternatively, the excellent outcomes in highly sensi-
tized patients bridged to transplant may be due primarily to
the current ways in which they are treated, including pro-
longed wait-list times to undergo desensitization therapy
and prospective crossmatching. Information on the percent-
age of patients who underwent a prospective crossmatch is
not well characterized in the UNOS database to better un-
derstand this issue.
Stehlik and colleagues15 examined the accuracy of a ‘‘vir-
tual’’ crossmatch program and identified a 92% negative
predictive value and 79% positive predictive value when
compared with 257 T-cell antihuman immunoglobulin
complement-dependent cytotoxic crossmatch tests. Subse-
quently, 14 sensitized patients received allografts after
a compatible ‘‘virtual’’ crossmatch with donors from distant
locations. Their outcomes were compared with 14 sensi-
tized patients who received organs after compatible pro-
spective serologic crossmatch, and similar rejection rates
and survival were found. These findings hold promise for
improving donor issues in highly sensitized patients, al-
though they warrant duplication in larger-scale studies be-
fore widespread use.
There are conflicting reports regarding the impact of de-
vice type on formation of anti-HLA antibodies and PRA
levels. George and colleagues16 evaluated 60 patients who
were matched on comorbidities. They detected an increase
in PRA post-LVAD insertion with the XVE device but no in-
crease for the HMII device. There were fewer rejection ep-
isodes post-OHT in the HMII group in that study, althoughI* Class II*
I P value HR 95% CI P value
62 .9 0.69 0.32–1.51 .3
04 .02 1.02 1.00–1.04 .05
ce — — Reference —
85 .3 1.38 0.92–2.08 .1
44 .7 1.62 0.84–3.10 .1
ce — — Reference —
15 <.01 2.10 1.37–3.21 <.01
60 .7 1.68 0.83–3.40 .1
50 <.01 1.20 1.08–1.34 <.01
07 .9 1.03 0.98–1.08 .2
24 .04 1.67 1.12–2.46 .01
97 .1 2.09 0.82–5.36 .1
35 .03 1.16 1.00–1.33 .04
59 .8 0.90 0.57–1.42 .6
62 .5 1.19 0.83–1.71 .3
ormed with same risk factors in class I model examining class I PRA activity and class
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firmed these findings in 75 patients bridged to transplant,
but in that study only 11 patients received the HMII. In con-
trast, Kumpati and colleagues17 found that device type did
not affect sensitization in a large series of 239 patients
with an LVAD; however, that study spanned a broader
time period and examined other devices in addition to the
current most widely used HMII device.17
Our study builds on these previous findings because the
UNOS database distinguishes between class I and class II
PRA activity beginning in 2004 and continuing to the pres-
ent. Thus, we confined our study to include these years
only. When comparing highly sensitized patients, we chose
more than 25% as the cut-point. There is no consensus
definition on what threshold defines high sensitization,
but most studies use 10% or 25%. We did examine strata
of PRA activity (0%, 1%–10%, 11%–25%,>25%) so as
not to lose sensitivity in the analysis, but the multivariable
models with the most explanatory power incorporated
PRA activity as a categoric variable (0% vs>25%). To
evaluate extremely sensitized patients, patients with PRA
greater than 90% were compared with patients with
PRA 0%, and we observed similar findings. In regard to
the influence of device type, we detected higher PRA ac-
tivity in patients with an XVE for class II PRA activity
only. Our study in part supports the findings by other inves-
tigators, although we were unable to account for pre-LVAD
PRA activity.
There were few other baseline differences in characteris-
tics between nonsensitized and sensitized patients. Women
were more likely to have high PRA levels, consistent with
pregnancy being a sensitizing event. In addition, African-
American recipients were more likely to have high class
I and class II PRA levels. Past studies have documented
difficulty with HLA matching and poorer long-term sur-
vival in African-American OHT recipients.18,19 Although
sensitization seems more prevalent in African-American
recipients, in our study high PRA levels did not affect
post-OHT survival in patients bridged to transplant. Thus,
biologic mechanisms other than PRA activity are likely
combined with socioeconomic factors to contribute to this
outcome disparity.
Multivariable Analysis
Risk-adjusted multivariable Cox regression analysis as-
sessed the impact of potential confounding variables on
30-day and 1-year survival. Weiss and colleagues20 recently
developed a quantitative recipient risk index (IMPACT) for
OHT recipients, and many of these variables were selected
for inclusion in our multivariable analysis. For 1-year sur-
vival, older recipient age, recipient creatinine, African-
American race, pre-OHT infection, and longer allograft
ischemic time all increased the hazard of 1-year mortality.
High PRA activity, whether class I or II, did not1242 The Journal of Thoracic and Cardiovascular Surindependently affect the risk of mortality for 30-day or
1-year mortality. Although the absolute differences were
small, the distribution of recipient age, race, and serum cre-
atinine (for class II only) did differ by PRA activity levels.
However, these baseline differences should have been ac-
counted for in the multivariable analysis. We examined de-
vice type and center volume in the model because these
factors have influenced outcomes in other studies.6,21
Bull and colleagues6 found worse mortality in sensitized
patients with idiopathic cardiomyopathy, so we performed
a subgroup analysis in patients with this heart failure cause
only.6 In contrast with their findings, our analysis did not
show increased mortality in highly sensitized patients, and
device type did not seem to affect the risk of 30-day or
1-year mortality.
Limitations
Because of the retrospective study design, we are unable
to assert that all possible confounders have been examined.
The UNOS dataset is enriched with many variables avail-
able for analysis, although it is possible that potentially im-
portant variables are not included in this analysis.
Furthermore, large registry databases rely on accurate cod-
ing. The assumption is that any coding errors or missing
data present in the database will occur randomly and thus
do not render any bias. If this assumption is incorrect, resid-
ual bias may have influenced our conclusions. To mitigate
the effects of missing data, we did not incorporate variables
with more than 10% missing data into the regression
analysis.
PRA titers are still routinely performed, although with
advancements in immunogenetics laboratories, newer
methods may replace the PRA activity titer. Currently, there
are different assays used in various immunogenetics labora-
tories, leading to variability in reporting. Although this var-
iability is a limitation of our study, this analysis does
incorporate the largest number of patients bridged to trans-
plant undergoing OHT with available PRA information. In
addition, the PRA information included in the UNOS data-
base does not permit us to discern baseline levels before
LVAD placement. PRA titers are frequently obtained at
multiple times during LVAD support, because transfusions,
additional surgical procedures, and the presence of infec-
tion may dramatically alter the antibody levels. The
UNOS database is limited in that we are unable to determine
how antibody levels may have changed over the duration of
LVAD support and in relation to specific clinical events. The
duration of pre-OHT LVAD support and mortality during
the pre-OHT support period are unknown. Many patients
with high PRA may not be offered transplant and die as
a result.
We are also unable to determine specific treatment algo-
rithms that patients with high PRAmay have undergone, in-
cluding desensitizing therapies. Therefore, we chose togery c November 2011
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ine the immunologic status of the recipient just before im-
plantation of the allograft, regardless of prior therapies or
PRA levels. It is also impossible to ascertain if a crossmatch
was performed retrospectively or prospectively. Further-
more, information on ‘‘virtual’’ crossmatching is not coded
in the UNOS database, although this technique is increas-
ingly being used and may enhance donor–recipient match-
ing in the future. Although these data suggest that high PRA
does not influence short-term survival, additional informa-
tion regarding treatment algorithms and crossmatch prac-
tices are needed to definitively support a more liberal
strategy for patients bridged to transplant with high PRA
activity.
This study has a relatively short follow-up period. We
chose to begin the study in 2004, because before that time
there were few HMII or XVE recipients bridged to trans-
plant in the UNOS registry. Because sensitization may in-
fluence chronic rejection, additional follow-up is
warranted to determine whether high PRA levels affect
longer-term outcomes, such as 5-year survival.CONCLUSIONS
This is the largest modern study to examine the impact of
detailed PRA information in patients bridged to OHT with
an LVAD. High PRA levels do not affect drug-treated rejec-
tion episodes in the first year post-OHT; however, there is an
associated higher rate of PGD, regardless of device type.
Highly sensitized patients bridged to transplant experience
excellent short-term survival outcomes after OHT.T
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Dr Carmelo Milano (Durham, NC). Dr Shah and colleagues
from Johns Hopkins ought to be commended for their effort to
use the UNOS database. A large number of resources are required
to maintain the UNOS database. These data have not been exten-
sively analyzed. But recently, Dr Shah and colleagues have pub-
lished several reviews of these data that have provided us with
useful clinical knowledge.
The current study shows that heart transplant recipients who un-
derwent LVAD bridging experienced equivalent posttransplant
survival outcomes regardless of device type and PRA status; how-
ever, the high PRA group experienced a longer wait-list time rel-
ative to the low PRA or zero PRA group. This observation is
important and indicates the importance of the pretransplant
LVAD support period. I have one slide that I wanted to show.
This slide illustrates survival outcomes from a recent bridged to
transplant LVAD device trial. This experimental device was im-
planted in approximately 140 patients, and the outcomes over
the course of 1 year are demonstrated. It is important to note
that less than 30% of the patients actually go on to receive a trans-
plant during the first year of support. So when we talk about bridg-
ing patients to transplant, it is a long bridge, with less than 30% of
patients receiving a transplant during the first year.
Furthermore, it is notable that the mortality during device sup-
port is less than 5% in this study, which is actually comparable todiovascular Surgery c Volume 142, Number 5 1243
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may no longer mean that overall survival is reduced for patients
with an increased PRA.
My first question is, can the authors display survival outcomes
beginning from the time of the LVAD implantation rather than
from the time of transplant? The cumulative LVAD and transplant
period should be evaluated to determine the impact of factors such
as increased PRA or device type on overall survival. Did these fac-
tors, increased PRA or the device type, affect outcomes when we
look at outcomes beginning from the time of the device implant
rather from the time of transplant?
Dr George. One of the great things about the UNOS database
is that it contains so many variables. One of the limitations is that
the number of variables is finite. Unfortunately, duration of ven-
tricular assist device support is not available. Also, PRA data are
only included for patients who ultimately receive transplants. So
although there are data on patients who are bridged to transplant
who do not ultimately undergo transplantation, we don’t actually
know what their PRA levels are unless they ultimately receive
a transplant. So as you suggest, there is an increased wait-list
time, and we would expect that to correlate with an increased
wait-list mortality. The data are simply not available in the data-
base to evaluate that.
DrMilano.My second question relates to posttransplant infec-
tion outcomes. Patients with high PRA frequently are treated with
different and increased immunosuppressive therapies, for exam-
ple, plasmapheresis, which may increase infection complications
during the posttransplant period. Were the rates of infection differ-
ent between the 2 groups?
Dr George.We anticipated the infection rate to be higher in the
highly sensitized group for that reason. Surprisingly, the infection
rates are the same. As measured by class I, nonsensitized patients
had an infection rate of approximately 33% and highly sensitized
patients had an infection rate of approximately 35%, and the dif-
ference was not significant.
Dr Milano. My third question is, can the authors detect an ef-
fect from the advent of virtual crossmatch technology versus for-
mal prospective crossmatch for high PRA LVAD recipients? As
we transition to this newer technology, does that seem to be having
a positive impact on, for example, wait-list times?
My last question is a more practical, simple question. Many in-
stitutions have these LVAD recipients who are highly sensitized.
These patients present challenges. We know that their period of
LVAD support is prolonged. Given the data that you have pre-
sented, has that changed your management? Have you changed
your management strategies for these difficult patients on the basis
of these data?
DrGeorge. First, in addressing virtual crossmatch data, we cer-
tainly agree that virtual crossmatching is a significant advance in
this science. We think it is very important, and it is what we prac-
tice at our institution. Unfortunately, whether or not patients un-
derwent virtual crossmatching is another variable that is not
available in the database.
In terms of our own practice, it is our practice to use virtual
crossmatching, or at least declare at the outset which HLA types
will simply be unacceptable for a given recipient. We use prospec-
tive crossmatching sparingly, really only for local donors when
time will permit. All of our patients undergo retrospective1244 The Journal of Thoracic and Cardiovascular Surcrossmatching, and all of our sensitized patients receive intrave-
nous immunoglobulin on the way to the operating room. We
then treat them postoperatively with rituximab, and depending
on their crossmatch data, they will get plasmapheresed.
We have always been aggressive about performing transplanta-
tions in sensitized patients, because it has been our sense that these
patients do well, and I think the results of this study really confirm
that practice. So we will continue to be aggressive with highly sen-
sitized patients.
Dr Robert Higgins (Columbus, Ohio). I think the previous
questions were important, but I will ask a slightly different ques-
tion. Did you have any information about prospective crossmatch
in this series as it relates to the whole group, because I think it is
used in many centers before transplant? And the other question
is about prospective management of patients with high PRA,
whether they received additional therapies before transplantation.
I suspect that may be one of the shortcomings of the UNOS data-
base. But a very nice study.
Dr George. In answering your second question, data relating to
desensitization therapies used preoperatively, perioperatively, and
postoperatively are not available in the UNOS database. That is
something we would certainly be interested in looking at, because
it would be interesting to know which treatments are really im-
proving outcomes, and the database in its current form is not
able to answer those questions.
My answer is similar in regard to the prospective crossmatch-
ing. There is a variable in the database about crossmatching, but
there is no designation of prospective versus retrospective. So
there is no way to know which patients were prospectively cross-
matched and how they did in comparison with thosewhowere only
retrospectively crossmatched.
DrR. Duane Davis (Durham, NC). The idea of using a compos-
ite end point that is essentially just the highest of the 2 classes is
probably not appropriate given that although they are not indepen-
dent because of linkage and so forth, it really is closer to an inde-
pendent variable. So that, in fact, if you were 50% class I and 50%
class II, then you really are closer to a 75% PRA. That gets to my
question. Did you do any sensitivity analysis around the differing
levels of PRA, were there differences in adverse outcomes, partic-
ularly at very high levels of PRA?
And then another comment regarding the interpretation of PRA,
which doesn’t mean the same as having a lot of antibody. It means
that you have broad specificities, and it may not be high antibody
titers at all.
My final comment will be just a plea to the thoracic community.
One of the problems you run into with this data set is that we don’t
mandate PRA being collected at the time transplant candidacy is
done. Therefore, we don’t have that data, and we actually can’t
say what is the impact of being sensitized in terms of dying while
waiting for an organ. The only thing we can say is that we have got-
ten good enough that for the majority of patients we are not having
adverse outcomes, at least in the short term.
DrGeorge.Let me begin by echoing your last comment that the
UNOS data set has different tiers of information, the first tier being
mandatory reporting and the other tier being voluntary, and it does
become difficult in analyzing these data sets when we are missing
significant amounts of data in the other tiers. So I do want to echo
that comment.gery c November 2011
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those comments. There is an approximately 10% incidence of pa-
tients who are either highly sensitized in one class and not sensi-
tized in the other, and we weren’t entirely sure what to do with
those patients. And we didn’t want to completely ignore this issue
and then potentially bias one group or the other, because although
they were nonsensitized in one group, they were highly sensitized
in another. We wanted some way to take that into account. In the
literature we found several articles that used a composite end point
such as we have. But I do accept your criticism that that may not be
the best way to do this.
The second point about the PRA cut point, any PRA cut point
would be somewhat arbitrary in the sense that there are nonsensi-
tized patients, and then there are patients that have some degree of
sensitization. Previous literature has suggested different cut points;
10% and 25% are 2 commonly used numbers in the literature.
In deciding what cut point to use, we wanted to use a high
enough level that we thought the PRA would at least potentially
be significant and potentially have an impact on outcomes, and
at the same time we wanted to keep the number low enough that
we wouldn’t lose the power to detect that difference if such a dif-
ference existed. So we ended up settling on 25%. However, that
said, in our initial analysis and in constructing our models, we
did use PRA as a continuous variable.We also stratified it a number
of different ways and finally as a dichotomous variable, as weThe Journal of Thoracic and Carpresented. We evaluated our models, and the model with the great-
est explanatory power was the one stratified at 25%. But I do again
acknowledge the criticism that this is a somewhat arbitrary cut
point.
Finally, I want to agree with your point that PRA is sort of
a crude measure of sensitization. We recognize that, and we be-
lieve that the future of this science lies in specific anti-HLA anti-
bodies and virtual crossmatching. But for now, PRA is the most
commonly used measure, so we used it in this study.
DrOctavio Pajaro (Phoenix, Ariz). Actually I was just going to
follow up on Dr Davis’s comments. I had similar questions, but
with the transition from cell-based assays to solid-based assays
and the difference in what we report as a PRA. Really, now we
are reporting something that is just the frequency of the allograft
in the UNOS population. So it means something different immu-
nologically than it did in 2004.
My question is, can you estimate how unpure your control group
is, because especially in hearts, unless you list an unacceptable an-
tigen, then there is no PRA reporting, and many centers won’t list
anybody with unacceptable antigens. So those patients will appear
as a zero PRA on the UNOS, but they are doing a virtual
crossmatch.
Dr George. We are limited in this kind of database analysis to
what is reported to the database. Sowe accept that as a limitation of
the study, that people may not be entirely truthful about the data.diovascular Surgery c Volume 142, Number 5 1245
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TABLE E1. Outcomes stratified by panel reactive antibody level
PRA 0% PRA>25% P value*
Wait-list time, d
PRA class I 123 (51–270) 203 (81–342) <.001
PRA class II 137 (56–280) 151 (68–281) .35
Composite PRA 122 (52–266) 200 (82–332) <.001
Drug-treated rejection
PRA class I 107/368 (29.0%) 25/72 (34.7%) .4
PRA class II 84/329 (25.5%) 13/37 (35.1%) .2
Composite PRA 95/342 (27.8%) 31/86 (36.1%) .1
Drug-treated infection
PRA class I 115/360 (31.9%) 28/78 (35.9%) .3
PRA class II 109/323 (33.8%) 15/42 (35.7%) .9
Composite PRA 104/333 (31.2%) 34/91 (37.4%) .4
*P value determined by rank-sum analysis for wait-list time and by Pearson chi-
square analysis for categoric outcomes.
TABLE E2. Cox multivariable proportional hazards regression for 30-day mortality
Variable
Class I* Class II*
HR 95% CI P value HR 95% CI P value
PRA>25% 1.14 0.57–2.30 .7 1.16 0.44–3.08 .8
Recipient age>60 y 1.55 0.86–1.54 .1 1.34 0.74–2.42 .3
Male recipient 0.93 0.43–2.00 .8 0.72 0.35–1.49 .4
Idiopathic cardiomyopathy — Reference — — Reference —
Ischemic cardiomyopathy 1.77 0.92–3.44 .08 2.10 1.10–4.01 .02
Congenital 3.22 1.29–7.97 .01 3.30 1.42–7.66 <.01
White — Reference — — Reference —
African-American 2.24 1.16–4.30 .02 2.05 1.08–3.92 .03
Hispanic 0.81 0.18–3.46 .8 1.49 0.52–4.26 .5
Recipient creatinine, mg/mL 1.28 1.06–1.54 <.01 1.23 1.06–1.43 <.01
Recipient bilirubin, mg/mL 1.02 0.95–1.09 .6 1.02 0.95–1.09 .6
Preoperative mechanical ventilation 4.23 1.24–14.46 .02 4.24 1.24–14.46 .02
Preoperative infection requiring IV antibiotics 1.25 0.66–2.39 .5 1.25 0.66–2.39 .5
HMII device 1.02 0.56–1.80 .9 1.03 0.56–1.80 .9
Allograft ischemic time, h 1.29 1.07–1.56 <.01 1.30 1.08–1.56 <.01
High annual center volume (>12) 0.77 0.34–1.73 .5 0.77 0.34–1.73 .5
HR,Hazard ratio; CI, confidence interval; IV, intravenous. *Cox multivariable analysis performed with same risk factors in class I model examining class I PRA activity and class
II model examining class II PRA activity.
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